{"preliminary_commentary":{"by_channel":{"x_thread":3},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":false},"commentary_summary":null,"drugs_tested":null,"indication":null,"name":"I-SABR","nct_id":"NCT03110978","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=i-sabr-nct03110978. The price is an estimate of verified statements from the commentary indexed so far. Final coverage is set when the report is built. You never pay more than quoted: if the report is delivered at a smaller size, you pay that size's price, and anything paid above it is refunded. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_rule":"Never more than quoted: the buyer pays the smaller of price_usd and the price the delivered edition is sold at.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":"Patients undergo stereotactic body radiation therapy over 1-2 weeks.","label":"Arm I (stereotactic body radiation therapy)","type":"EXPERIMENTAL"},{"description":"Patients undergo stereotactic body radiation therapy over 1-2 weeks. Beginning within 36 hours before or after the first fraction of stereotactic body radiation therapy, patients also receive nivolumab IV over 30 minutes on day 1. Cycles with nivolumab repeat every 4 weeks for up to 12 weeks in the absence of disease progression or unacceptable toxicity.","label":"Arm II (stereotactic body radiation therapy, nivolumab)","type":"EXPERIMENTAL"}],"collaborators":[],"completion_date":{"date":"2028-06-30","type":"ESTIMATED"},"conditions":["Lung Atypical Carcinoid Tumor","Lung Neuroendocrine Neoplasm","Lung Non-Small Cell Squamous Carcinoma","Minimally Invasive Lung Adenocarcinoma","Neuroendocrine Carcinoma","Recurrent Lung Adenocarcinoma","Recurrent Lung Large Cell Carcinoma","Recurrent Lung Non-Small Cell Carcinoma","Stage I Lung Cancer AJCC v8","Stage IA1 Lung Cancer AJCC v8","Stage IA2 Lung Cancer AJCC v8","Stage IA3 Lung Cancer AJCC v8","Stage IB Lung Cancer AJCC v8","Stage IIA Lung Cancer AJCC v8"],"enrollment":{"count":140,"type":"ACTUAL"},"has_results":false,"interventions":[{"name":"Nivolumab","otherNames":["BMS-936558","MDX-1106","NIVO","ONO-4538","Opdivo"],"type":"BIOLOGICAL"},{"name":"Stereotactic Body Radiation Therapy","otherNames":["SABR","SBRT","Stereotactic Ablative Body Radiation Therapy"],"type":"RADIATION"}],"last_update":"2026-06-22","lead_sponsor":"M.D. Anderson Cancer Center","official_title":"Phase II Randomized Clinical Trials Comparing Immunotherapy Plus Stereotactic Ablative Radiotherapy (I-SABR) Versus SABR Alone for Stage I, Selected Stage IIa, or Isolated Lung Parenchymal Recurrent Non-Small Cell Lung Cancer: I-SABR","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE2"],"primary_completion_date":{"date":"2028-06-30","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Event-free survival with events defined as local recurrence, regional recurrence, distant metastasis, secondary malignancy (including lung cancer), and death","timeFrame":"From the randomization date, assessed up to 5 years"}],"references":[{"citation":"Chang JY, Lin SH, Dong W, Liao Z, Gandhi SJ, Gay CM, Zhang J, Chun SG, Elamin YY, Fossella FV, Blumenschein G, Cascone T, Le X, Pozadzides JV, Tsao A, Verma V, Welsh JW, Chen AB, Altan M, Mehran RJ, Vaporciyan AA, Swisher SG, Balter PA, Fujimoto J, Wistuba II, Feng L, Lee JJ, Heymach JV. Stereotactic ablative radiotherapy with or without immunotherapy for early-stage or isolated lung parenchymal recurrent node-negative non-small-cell lung cancer: an open-label, randomised, phase 2 trial. Lancet. 2023 Sep 9;402(10405):871-881. doi: 10.1016/S0140-6736(23)01384-3. Epub 2023 Jul 18.","pmid":"37478883","type":"DERIVED"}],"start_date":{"date":"2017-06-26","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Stereotactic Body Radiation Therapy With or Without Nivolumab in Treating Patients With Stage I-IIA or Recurrent Non-small Cell Lung Cancer","url":"https://clinicaltrials.gov/study/NCT03110978"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.2","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/i-sabr-nct03110978"}